Zu den Inhalten springen

Klinik für Innere Medizin IHämatologie, Onkologie und Stammzelltransplantation

Allogene hämatopoetische Stammzelltransplantation

Dr. Miguel Waterhouse | Biochemiker
Telefon +49 (0) 761 270-36460
E-Mail miguel.waterhouse@uniklinik-freiburg.de
Sabine Enger | Techn. Assistentin
Telefon +49 (0) 761 270-35820
E-Mail sabine.enger@uniklinik-freiburg.de
Ingrid Huber | Techn. Assistentin
Telefon +49 (0) 761 270-36460
E-Mail ingrid.huber@uniklinik-freiburg.de

  • Microarray-Genomanalyse myeloischer Leukämiezellen im Rahmen der allogenen Stammzelltransplantation: zur Frage der "Alloresistenz" genomischer Veränderungen  
  • Functional and phenotypical characterization of donor lymphocytes used for infusion after allogeneic stem cell transplantation.  
  • PD1-ligand expression and interactions in AML patients relapsing after allogeneic stem cell transplantation.  
  • Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation
  • Plasma micro-RNAs as biomarker for graft-versus-host disease  

  • Untersuchungen zum Chimärismus nach reduzierter Konditionierung und allogener Stammzelltransplantation  
  • Toleranzinduktion durch CD4+CD25+ T-Lymphozyten nach allogener Stammzelltransplantation
  • Calcineurin-Inhibitor-freie GvHD Prophylaxe mit Everolimus und Mycophenolat zur GvHD-Prophylaxe und Toleranzinduktion nach allogener Stammzelltransplantation  
  • Allogene Stammzelltransplantation für Patienten mit primären Immundefekten
  • Hochdosis-Chemotherapie und autologe Stammzelltransplantation zur Erstlinientherapie von Patienten mit primären ZNS-Lymphomen

  • Finke, J., C. Schmoor, W. A. Bethge, H. Ottinger, M. Stelljes, L. Volin, D. Heim, H. Bertz, O. Grishina and G. Socie (2017). "Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial."
    Lancet Haematol 4(6): e293-e301.  
  • Fritsch, K., B. Kasenda, E. Schorb, P. Hau, J. Bloehdorn, R. Mohle, S. Low, M. Binder, J. Atta, U. Keller, H. H. Wolf, S. W. Krause, G. Hess, R. Naumann, S. Sasse, C. Hirt, M. Lamprecht, U. Martens, A. Morgner, J. Panse, N. Frickhofen, A. Roth, C. Hader, M. Deckert, H. Fricker, G. Ihorst, J. Finke and G. Illerhaus (2017). "High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)."
    Leukemia 31(4): 846-852.
  • Kasenda, B., G. Ihorst, R. Schroers, A. Korfel, I. Schmidt-Wolf, G. Egerer, L. von Baumgarten, A. Roth, J. Bloehdorn, R. Mohle, M. Binder, U. Keller, M. Lamprecht, M. Pfreundschuh, E. Valk, H. Fricker, E. Schorb, K. Fritsch, J. Finke and G. Illerhaus (2017). "High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group."
  • Rathmann, S., C. Keck, C. Kreutz, N. Weit, M. Muller, J. Timmer, S. Glatzel, M. Follo, M. Malkovsky, M. Werner, R. Handgretinger, J. Finke and P. Fisch (2017). "Partial break in tolerance of NKG2A-/LIR-1- single KIR+ NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation."
    Bone Marrow Transplant.  
  • Strussmann, T., K. Fritsch, A. Baumgarten, T. Fietz, M. Engelhardt, R. Mertelsmann, G. Ihorst, J. Duyster, J. Finke and R. Marks (2017). "Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation."
    Br J Haematol.  
  • Waterhouse M, Pfeifer D, Follo M, Duyster J, Schäfer H, Bertz, H, Finke J. Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation.
    Clin Chem Lab Med. 2017 Jan 18 [Epub ahead of print]  
  • Waterhouse M, Bartsch I, Bertz H, Duyster J, Finke J. Cerebrospinal fluid chimerism analysis in patients with neurological symptoms after allogeneic cell transplantation.
    Bone Marrow Transplant. 2016 Jan;51(1):127-31  
  • Waterhouse M, Follo M, Pfeifer D, von Bubnoff N, Duyster J, Bertz H, Finke J. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Ann Hematol. 2016 Apr;95(5):739-44 
  • Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
    Lancet Haematol. 2016;3(8):e388-397.
  • Hasskarl J, Zerweck A, Wasch R, Ihorst G, Bertz H, Finke J. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft.
    Bone Marrow Transplant. 2012;47(2):277-282.    
  • Finke J, Schmoor C, Bertz H, et al. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2016;51(6):771-777
  • Waterhouse M, Bertz H, Finke J. A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1 and FLT3-ITD mutations after allogeneic stem cell transplantation.
    Ann Hematol. 2014 Feb;93(2):293-8  
  • Duque-Afonso J, Ihorst G, Wasch R, et al. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
    Bone Marrow Transplant. 2013;48(8):1098-1103.
  • Waterhouse M, Duque-Afonso J, Wäsch R, Bertz H, Finke J. Soluble HLA-G molecules and HLA-G 14bp polymorphism after allogeneic hematopoietic cell transplantation.
    Transplant Proc 2013. Jan-Feb;45(1):397-401  
  • Christopoulos P, Schmoor C, Waterhouse M, Marks R, Wäsch R, Bertz H, Finke J. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
    Bone Marrow Transplant. 2013. Jul;48(7):901-7  
  • Waterhouse M, Kunzmann R, Torres M, Bertz H, Finke J. An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation.
    Clin Chem Lab Med 2012. 2012 Jul[Epub ahead of print]      
  • Waterhouse M, Themeli M, Bertz H, Zoumbos N, Finke J, Spyridonidis A. Horizontal DNA transfer from donor to host cells as an alternative mechanism of epithelial chimerism after allogeneic hematopoietic cell transplantation.
    Biology of Blood and Bone Marrow Transplantation 2011. Mar;17(3)319-329.  
  • Themeli M, Waterhouse M, Finke J, Spyridonidis A. DNA chimerism and its consequences after allogeneic hematopoietic cell transplantation.
    Chimerism 2011. Jan;2(1):25-28  
  • Waterhouse M, Samek E, Torres M, Bertz H, FinkeJ. Diagnostic utility of a soluble cytokeratin 18 assay for gastrointestinal graft-vs-host disease detection.
    Clin Chem Lab Med 2011. Oct;49(10):1695-97  
  • Waterhouse M, Pfeifer D, Pantic M, Emmerich F, Bertz H, Finke J. Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation.
    Biol Blood Marrow Transplant 2011. Oct;17(10):1450-1459  
  • Illerhaus,G., Muller,F., Feuerhake,F., Schafer,A.O., Ostertag,C., and Finke,J.  High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
    Haematologica 93, 147-148.(2008).
  • Marks,R., Potthoff,K., Hahn,J., Ihorst,G., Bertz,H., Spyridonidis,A., Holler,E., and Finke,J.M.  Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Blood 112, 415-425.(2008).
  • Finke,J., Bethge,W.A., Schmoor,C., Ottinger,H.D., Stelljes,M., Zander,A.R., Volin,L., Ruutu,T., Heim,D.A., Schwerdtfeger,R., Kolbe,K., Mayer,J., Maertens,J.A., Linkesch,W., Holler,E., Koza,V., Bornhauser,M., Einsele,H., Kolb,H.J., Bertz,H., Egger,M., Grishina,O., and Socie,G.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Lancet Oncol. 10, 855-864.(2009).
  • Lubbert,M., Bertz,H., Ruter,B., Marks,R., Claus,R., Wasch,R., and Finke,J.  Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Bone Marrow Transplant. 44, 585-588.(2009).
  • Schnitzler,M., Hasskarl,J., Egger,M., Bertz,H., and Finke,J.  Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.
    Biol. Blood Marrow Transplant. 15, 910-918.(2009).
  • Waterhouse,M., Themeli,M., Metaxas,Y., Lagadinou,E.D., Finke,J., and Spyridonidis,A.  Horizontal DNA and mRNA transfer between donor and recipient cells after allogeneic hematopoietic cell transplantation?
    Front Biosci. 14, 2704-2713.(2009).
  • Finke,J. and Nagler,A.  Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
    Leukemia 21, 1357-1362.(2007).
  • Illerhaus,G., Marks,R., Ihorst,G., Guttenberger,R., Ostertag,C., Derigs,G., Frickhofen,N., Feuerhake,F., Volk,B., and Finke,J.  High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    J. Clin. Oncol. 24, 3865-3870.(2006). Zeiser,R. and Finke,J.  Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
    Eur. J Cancer 42, 1601-1611.(2006).


  • Finke J. and Mertelsmann,R. (2017) Hematopoietic growth factors after hematopoietic cell transplantation: Are they useful?.  Hematopoietic cell transplants 1st edition H.M. Lazarus, R.P. Gale, A. Keating, A. Bacigalupo, R. Munker, K Atkinson, S.A. Abutalib eds, Cambridge Universitiy Press, chpt. 14, pp119 ff
  • Finke,J. and Mertelsmann,R. (2016). Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation.,  Thomas´ Hematopoietic Cell Transplantation, 5th edition, S.J.Forman, R.S.Negrin, J.H Antin and F.R.Appelbaum, eds., Wiley-Blackwell, chpt 42, pp. 480 ff.
  • Finke, J. (2015) T Zell Depletion. Hämatopoetische Stammzellen, 1st Edition, W. Herr, M. Theobald, G. Ehninger, H. Einsele, R.G. Myerer, eds, Kapitel 19.2 p 94ff  
  • Finke, J. u. G. Illerhaus (2015) ZNS-Lymphome. Depletion. Hämatopoetische Stammzellen, 1st Edition, W. Herr, M. Theobald, G. Ehninger, H. Einsele, R.G. Myerer, eds, Kapitel 39.3 p 279 ff.
  • Finke,J. (2009). Hodgkin´s disease and non-Hodgkin´s lymphoma. In Hematopoietic Stem Cell Transplantation, J.Treleaven and A.J.Barrett, eds. (Edinburgh: Churchill Livingstone Elsevier), pp. 97-104.